Published: December 2024 | Last updated: April 2026
Finding out you have hepatitis C during a prenatal visit is unsettling. You probably were not expecting it. You may have no symptoms. And the first questions are almost always the same: will my baby be infected, can I still breastfeed, and is there anything I should be doing about it right now?
The short version: vertical transmission of hepatitis C virus (HCV) happens, but it is uncommon. Modern direct-acting antivirals cure most hepatitis C infections in two to three months, and that treatment is yours to plan after delivery. Universal screening in every pregnancy (now the standard recommendation from the U.S. Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists since 2020) is what catches HCV early enough to coordinate the right care for both of you.
This guide walks through what the current research and public-health guidance actually say about hepatitis C and pregnancy, the parts that have changed in the last few years, and what to actually do at each stage.
How serious is hepatitis C during pregnancy, and what should I do about it?
Vertical transmission of hepatitis C happens in roughly 6% of births to HCV-positive parents, rising to about 11% when the parent also has HIV. There is no hepatitis C vaccine, and direct-acting antivirals are not currently used during pregnancy because of limited safety data. The standard plan is: universal screening early in pregnancy, careful obstetric management to avoid transmission-raising practices, normal vaginal delivery in most cases, breastfeeding when nipples are intact, and direct-acting antiviral treatment after birth that cures over 95% of cases in 8 to 12 weeks.
Why hepatitis C deserves its own pregnancy conversation
Hepatitis C is a blood-borne virus that infects the liver. Most people who have it feel completely well for years, sometimes decades, before any symptoms appear. The CDC estimates roughly 2.4 million people are living with hepatitis C in the United States, and a meaningful share do not know they have it.
Pregnancy changes the conversation in three specific ways. First, the most effective hepatitis C medications (called direct-acting antivirals, or DAAs) have not been studied enough during pregnancy to be routinely recommended. Second, there is no vaccine for hepatitis C, so the protective tools used at delivery for hepatitis B (vaccine plus immune globulin within 12 hours) are not options here. Third, the test that tells you whether your baby is actually infected runs on a different timeline than most newborn screening, with current guidance now favoring a viral RNA test at 2 to 6 months of age.
So a hepatitis C diagnosis during pregnancy is something to plan around, not panic about. The clinical pathway is well-established; it just looks different from the hepatitis B protocol many people have heard more about.
How vertical transmission actually works
Vertical (mother-to-child) transmission of hepatitis C means the virus passes from the pregnant person to the baby, usually around the time of birth rather than earlier in pregnancy. The most-cited figure from systematic reviews and the CDC is roughly 6%, meaning about six in every hundred babies born to HCV-positive parents test positive themselves.
That baseline shifts with a few specific risk factors:
- HIV co-infection. When the parent is positive for both HCV and HIV, the transmission rate roughly doubles to around 11%. Antiretroviral therapy for HIV reduces, but does not eliminate, this added risk.
- High HCV viral load. Parents with detectable HCV RNA at delivery are more likely to transmit than parents whose viral load is low or undetectable.
- Prolonged rupture of membranes and internal fetal monitoring (fetal scalp electrodes, scalp blood sampling) have been linked to higher transmission in some studies, which is why most providers avoid them when alternatives exist.
What does not meaningfully change the risk, based on current evidence: planned cesarean delivery. Analyses summarized by the CDC and ACOG have found no clear benefit to scheduled C-section over vaginal delivery for HCV-positive parents when other obstetric indications are absent. You do not need to plan major abdominal surgery to protect your baby from hepatitis C.
This article is published by stdrapidtestkits.com, which sells at-home rapid hepatitis tests and other STI screens. Recommendations here reflect what the kits genuinely fit (screening for non-pregnant household contacts, partners, or anyone wanting to confirm status), not a sales target. Pregnant readers should always pair home testing with prenatal care from a licensed provider.
Universal screening in every pregnancy: what changed in 2020
For decades, hepatitis C screening during pregnancy was risk-based: only people who reported injection drug use, certain transfusion histories, or other recognized risk factors were tested. That approach missed a lot of people, because hepatitis C is silent and many parents have no idea they were ever exposed.
In 2020 the CDC updated its guidance to recommend universal hepatitis C screening for every pregnant person, every pregnancy, ideally at the first prenatal visit. The American College of Obstetricians and Gynecologists (ACOG) followed with a Practice Advisory aligning with the CDC recommendation. That is why so many parents are now learning about hepatitis C during a routine prenatal panel rather than because they had any reason to suspect it.
The screening pathway is straightforward:
| Test | What it measures | What a positive result means |
|---|---|---|
| HCV antibody (anti-HCV) | Whether your immune system has ever seen hepatitis C virus | Either current infection or past infection that cleared. Always followed by an RNA test. |
| HCV RNA (viral load) | Whether hepatitis C virus is actively present in your blood right now | Active hepatitis C infection. Quantifies how much virus is circulating. |
| HCV genotype | Which strain of hepatitis C you have | Used historically to plan treatment. Less critical with modern pan-genotypic DAAs. |
| Liver enzymes (ALT, AST) | Whether the liver shows signs of inflammation | Helps the care team decide how closely to monitor your liver during pregnancy. |
Why direct-acting antivirals wait until after birth
Direct-acting antivirals have transformed hepatitis C treatment. Pan-genotypic regimens such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir cure over 95% of patients in 8 to 12 weeks of oral therapy, with relatively few side effects.
Despite that record, current guidance from the CDC, ACOG, and the AASLD/IDSA hepatitis C guidance panel is to not use DAAs routinely during pregnancy. The reason is sample size: large randomized trials in pregnant populations have not been completed, so safety in pregnancy is not formally established. Studies of sofosbuvir-based regimens during pregnancy are underway, and clinical trial enrollment is reasonable to ask your provider about, but DAAs in pregnancy outside a trial setting are not standard practice in 2026.
What this means in practice: most pregnant people with hepatitis C are observed (with liver enzyme and viral load monitoring) during pregnancy, and treated with DAAs after delivery. A typical timeline is treatment in the early postpartum months, often coordinated with pediatric follow-up for the baby. Postpartum cure rates match the general adult population.
Your birth plan: what the evidence supports
For an HCV-positive parent without other complications, current obstetric guidance points toward a fairly standard birth plan with a few targeted modifications.
Vaginal delivery is generally safe. Planned cesarean is not recommended solely to prevent HCV transmission, because the data do not show a clear protective effect. If a C-section is needed for other reasons (breech presentation, prior cesarean, fetal distress), that decision is made on its own merits.
Avoid invasive fetal monitoring when possible. Fetal scalp electrodes and scalp blood sampling create a small additional opportunity for blood-to-blood contact, and most providers will offer external monitoring instead when labor allows.
Limit prolonged rupture of membranes. If your water breaks well before active labor, the obstetric team may recommend interventions to keep the interval before delivery shorter than it might be otherwise.
Co-infection planning. If you also have HIV, the obstetric and infectious-disease teams will coordinate the delivery plan around HIV management, which has its own well-defined antiretroviral and delivery-mode protocols.
Tell your obstetric provider your HCV status as soon as you know it, so the labor and delivery team can plan around the modifications above.
- Inform your obstetric team of your HCV status as early in prenatal care as possible.
- Plan for vaginal delivery unless other obstetric indications require a C-section.
- Request external fetal monitoring rather than internal scalp electrodes when labor allows.
- Discuss strategies to limit the interval between membrane rupture and active delivery.
- Coordinate care with infectious-disease specialists if you also have HIV.
- Confirm the pediatric team knows your HCV status before discharge for infant follow-up planning.
Breastfeeding with hepatitis C: usually safe, with one caveat
The CDC, the American Academy of Pediatrics, and the World Health Organization all state that hepatitis C is not a contraindication to breastfeeding. Hepatitis C virus has not been shown to transmit through breast milk in healthy nipples, and the developmental and immune benefits of breastfeeding are well documented.
The one caveat is straightforward and has nothing to do with the milk itself: if your nipples are cracked or bleeding, the situation has shifted from a milk-only exposure to a potential blood exposure. Most lactation guidance recommends temporarily pumping and discarding milk from the affected side until the skin heals, then resuming breastfeeding normally.
If you are taking direct-acting antivirals postpartum and want to keep breastfeeding, that is a specific conversation to have with your hepatologist. Some regimens have minimal pediatric exposure data and providers handle this differently.
Testing your baby: what the new timeline looks like
If you are HCV-positive, your baby's pediatrician will plan a testing pathway. Under the current CDC recommendation:
- HCV RNA (nucleic acid test, or NAT) at 2 to 6 months of age. A negative result strongly suggests the baby was not infected, especially when confirmed with a second negative result.
- An HCV antibody test at 18 months can be added as a final confirmation if there is any remaining uncertainty.
- Babies who test positive are followed by a pediatric hepatologist or infectious-disease specialist, with treatment options available once the child is at least 3 years old.
About 94% of babies born to HCV-positive parents test negative on these tests, and the pathway is designed mainly to confirm those negative results while reliably catching the smaller share of infants who do need follow-up.
The older guidance was to test babies for hepatitis C antibody at 18 months of age. This delayed diagnosis significantly because maternal antibodies cross the placenta and need time to clear before an antibody test reflects the baby's actual status.
In November 2023 the CDC issued updated guidance recommending hepatitis C RNA (viral) testing at 2 to 6 months of age, which detects infection directly rather than waiting for the antibody window. This shift means infected babies can be identified, monitored, and (after age 3, when DAAs are FDA-approved for pediatric use) treated meaningfully earlier than under the older protocol.
Talking to your partner without panic
If you have just received an HCV diagnosis through prenatal screening, telling your partner can feel heavier than the diagnosis itself. The right framing is direct and clinical: hepatitis C is a blood-borne virus that the CDC now screens for in every pregnancy, you do not necessarily know the source of your infection, and your partner should be tested as a matter of routine, not blame.
A short script that lands well:
"My prenatal panel came back positive for hepatitis C. The CDC now tests every pregnancy for it because most people who have it have no symptoms. I do not know how I got it, and the doctor said you should get tested too, just to know your own status. There is treatment for me after the baby is born that cures it in about three months."
Sexual transmission of hepatitis C between heterosexual monogamous partners is uncommon (the virus is meaningfully less efficient at sexual spread than HIV or hepatitis B), but it does happen, particularly when blood contact is involved. Testing a partner is a one-time check, not an ongoing concern.
There is no hepatitis C vaccine, so unlike hep B, you cannot vaccinate close contacts to protect them. Partners and household contacts who test negative simply remain so by avoiding direct blood-to-blood contact with you (sharing razors, toothbrushes, manicure tools), which is generally easy to manage at home.
Hepatitis C testing is now recommended for all adults at least once during their lifetime and for all pregnant persons during each pregnancy, except in settings where the prevalence of HCV infection is less than 0.1%.
Your postpartum cure plan
The window your hepatitis C team has been waiting for opens after delivery. Here is what a typical postpartum HCV plan looks like.
Confirmatory testing. Before starting DAAs, the team rechecks HCV RNA and liver enzymes. About 15 to 25% of people clear hepatitis C on their own without treatment, and a small number find that postpartum bloodwork shows spontaneous clearance.
Choosing a regimen. Pan-genotypic DAA regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) are the modern default. Treatment duration is 8 or 12 weeks depending on regimen and any co-existing liver factors. Cure (defined as undetectable HCV RNA 12 weeks after finishing treatment) is achieved in over 95% of patients.
Coordinating with breastfeeding. Many parents complete breastfeeding before starting DAAs, but this is not universal. The decision involves your hepatologist, your pediatrician, and the specific regimen being considered.
Monitoring after cure. Once cured, hepatitis C does not return on its own. You can be re-infected through new blood exposure, but the virus you cleared is gone. Annual liver follow-up may continue for some patients depending on whether there was significant pre-treatment liver damage.
Future pregnancies. A parent who has been cured does not transmit hepatitis C to a future baby, since there is no virus to pass on. Many providers specifically time DAA treatment to fall between pregnancies for that reason.
Frequently asked questions
- Can hepatitis C cause complications in my pregnancy itself?
- Most pregnancies in HCV-positive parents proceed normally. Some studies have associated hepatitis C with slightly higher rates of cholestasis of pregnancy, gestational diabetes, and preterm birth, but the absolute increases are modest and prenatal care reduces them further. Severe maternal liver complications during pregnancy are uncommon.
- If my baby is born infected, will they have lifelong hepatitis C?
- Not necessarily. Roughly 25 to 40% of infants infected with hepatitis C clear the virus spontaneously by age 4 without any treatment. Those who do not clear it can be treated with pediatric direct-acting antivirals starting at age 3, with cure rates similar to adults.
- Should I have a C-section to protect my baby?
- Current evidence does not support planned cesarean delivery solely to prevent hepatitis C transmission. Vaginal delivery is the standard recommendation for HCV-positive parents without other obstetric indications, per ACOG and CDC guidance.
- Why can't I take direct-acting antivirals while pregnant?
- DAAs are not contraindicated absolutely, but large pregnancy safety trials have not been completed. The current standard of care is to defer treatment until after birth. Clinical trials of sofosbuvir-based regimens in pregnancy are ongoing, and asking your provider about trial eligibility is reasonable.
- Is breastfeeding safe with hepatitis C?
- Yes. Hepatitis C is not a contraindication to breastfeeding under guidance from the CDC, the AAP, and the WHO. The practical question parents ask is what to do if a nipple cracks during early nursing; the usual answer is to switch to the unaffected side until the broken skin heals, then resume normal feeding.
- When should my baby be tested for hepatitis C?
- Around 2 to 6 months of age. The pediatrician orders an HCV RNA (NAT) test rather than the older 18-month antibody test. This change reflects 2023 CDC guidance and means babies who do test positive can be linked to specialist care and (from age 3) curative treatment much earlier than in the past.
- Should my partner get tested?
- Yes. Sexual transmission of hepatitis C between monogamous partners is uncommon but possible. A one-time HCV antibody test for your partner is the standard recommendation. There is no vaccine for hepatitis C, so partners cannot be immunized in advance the way hep B partners can.
- Is hepatitis C curable after pregnancy?
- Yes. Modern direct-acting antiviral regimens cure over 95% of hepatitis C infections in 8 to 12 weeks of oral treatment. Most parents who are diagnosed during pregnancy complete treatment in the months after delivery and remain cured for life, with no transmission risk to future pregnancies.
- U.S. Centers for Disease Control and Prevention. Hepatitis C basics, transmission, screening recommendations, and treatment overview, including 2020 universal pregnancy screening guidance.
- Panagiotakopoulos L, et al. CDC Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children, United States, 2023. MMWR Recommendations and Reports, November 3, 2023, recommending HCV RNA (NAT) testing at 2 to 6 months of age.
- American College of Obstetricians and Gynecologists. ACOG aligns with the 2020 CDC universal HCV screening recommendation for all pregnant individuals; see ACOG's clinical guidance and practice advisory archive on viral hepatitis in pregnancy.
- World Health Organization. Hepatitis C fact sheet, including global epidemiology, transmission routes, and treatment effectiveness data.
- American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C, including the pregnancy and pediatric sections.
- U.S. National Institute of Diabetes and Digestive and Kidney Diseases. Hepatitis C overview, with sections on natural history, vertical transmission, and direct-acting antiviral treatment outcomes.
